Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel Free HEMO Stock Alerts

Hemogenyx Pharmaceuticals (HEMO) Competitors

Hemogenyx Pharmaceuticals logo
GBX 771 -14.00 (-1.78%)
As of 04:34 AM Eastern
Compare

HEMO vs. ARIX, BTG, SCLP, CIR, and TILS

Should you buy Hemogenyx Pharmaceuticals stock or one of its competitors? MarketBeat compares Hemogenyx Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Hemogenyx Pharmaceuticals include Arix Bioscience (ARIX), BTG (BTG), Scancell (SCLP), Circassia Group (CIR), and Tiziana Life Sciences (TILS). These companies are all part of the "biotechnology" industry.

How does Hemogenyx Pharmaceuticals compare to Arix Bioscience?

Hemogenyx Pharmaceuticals (LON:HEMO) and Arix Bioscience (LON:ARIX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Arix Bioscience'saverage media sentiment score.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
Arix Bioscience Neutral

0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 41.3% of Arix Bioscience shares are owned by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Comparatively, 20.7% of Arix Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Arix Bioscience has a net margin of 105.64% compared to Hemogenyx Pharmaceuticals' net margin of 0.00%. Arix Bioscience's return on equity of 6.41% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
Arix Bioscience 105.64%6.41%2.18%

Arix Bioscience has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Arix Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
Arix Bioscience£14.16M0.00£14.96M£0.11N/A

Hemogenyx Pharmaceuticals has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, Arix Bioscience has a beta of 1.05, suggesting that its share price is 5% more volatile than the broader market.

Summary

Arix Bioscience beats Hemogenyx Pharmaceuticals on 9 of the 10 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to BTG?

BTG (LON:BTG) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

BTG's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
BTGN/A N/A N/A
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

19.2% of BTG shares are owned by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 19.7% of BTG shares are owned by insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, BTG had 5 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 5 mentions for BTG and 0 mentions for Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 beat BTG's score of -0.10 indicating that Hemogenyx Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
BTG Neutral
Hemogenyx Pharmaceuticals Neutral

BTG currently has a consensus target price of GBX 160, suggesting a potential upside of 47.17%. Given BTG's stronger consensus rating and higher probable upside, research analysts clearly believe BTG is more favorable than Hemogenyx Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BTG
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Hemogenyx Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

BTG has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than BTG, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BTG£159.40M1.10N/A£6.0018.12
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

Summary

BTG beats Hemogenyx Pharmaceuticals on 11 of the 12 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Scancell?

Scancell (LON:SCLP) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Scancell's net margin of -116.98%. Scancell's return on equity of 90.29% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Scancell-116.98% 90.29% -45.28%
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

Scancell has a beta of 0.736, meaning that its share price is 26% less volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

In the previous week, Scancell had 1 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 1 mentions for Scancell and 0 mentions for Hemogenyx Pharmaceuticals. Scancell's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Scancell Neutral
Hemogenyx Pharmaceuticals Neutral

1.5% of Scancell shares are owned by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 15.5% of Scancell shares are owned by company insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Hemogenyx Pharmaceuticals has lower revenue, but higher earnings than Scancell. Scancell is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scancell£4.71M28.91-£6.75M-£0.55N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

Summary

Scancell beats Hemogenyx Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Circassia Group?

Hemogenyx Pharmaceuticals (LON:HEMO) and Circassia Group (LON:CIR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Circassia Group has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Circassia Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
Circassia Group£27.90M0.00N/A£0.01N/A

Circassia Group's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
Circassia Group N/A N/A N/A

In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Circassia Group'saverage media sentiment score.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
Circassia Group Neutral

Summary

Circassia Group beats Hemogenyx Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

How does Hemogenyx Pharmaceuticals compare to Tiziana Life Sciences?

Tiziana Life Sciences (LON:TILS) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tiziana Life Sciences has higher earnings, but lower revenue than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Tiziana Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tiziana Life Sciences-£3.60M0.00N/A-£16.30N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

Tiziana Life Sciences' return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Tiziana Life SciencesN/A N/A N/A
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

In the previous week, Tiziana Life Sciences' average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Tiziana Life Sciences Neutral
Hemogenyx Pharmaceuticals Neutral

Summary

Tiziana Life Sciences beats Hemogenyx Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Get Hemogenyx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HEMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

HEMO vs. The Competition

Export
MetricHemogenyx PharmaceuticalsBiotechnology IndustryMedical SectorLON Exchange
Market Cap£52.43M£524.63M£6.96B£2.77B
Dividend YieldN/A3.90%2.68%6.12%
P/E Ratio-4.523.1527.20368.14
Price / SalesN/A6,498.46578.1384,676.43
Price / Cash2.0513.1349.2527.89
Price / Book3,129.5886.9810.747.50
Net Income-£6.89K-£96.07M£3.59B£5.89B
7 Day Performance-0.52%-1.69%-1.92%-0.04%
1 Month Performance-0.90%1.37%2.23%-1.39%
1 Year Performance477.53%54.74%23.82%61.97%

Hemogenyx Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 771
-1.8%		N/A+497.5%£52.43MN/AN/A14
ARIX
Arix Bioscience
N/AN/AN/AN/A£183.73M£14.16M1,290.919
BTG
BTG
4.37 of 5 stars		GBX 108
flat		GBX 160
+48.1%		N/A£174.04M£159.40M18.004,690
SCLP
Scancell
N/AGBX 14.75
flat		N/A+37.8%£153.07M£4.71MN/A51
CIR
Circassia Group
N/AN/AN/AN/A£142.66M£27.90M3,400.00111

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:HEMO) was last updated on 7/17/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel